Hemogenyx Pharmaceuticals PLC Result of Annual General Meeting (2125D)
26 June 2021 - 12:32AM
UK Regulatory
TIDMHEMO
RNS Number : 2125D
Hemogenyx Pharmaceuticals PLC
25 June 2021
25 June 2021
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Result of Annual General Meeting
Hemogenyx Pharmaceuticals plc is pleased to announce that, at
the Annual General Meeting ("AGM") held earlier today, all
resolutions were duly passed. The numbers of votes for each
resolution are presented below.
AGM Voting Results
Ordinary Resolutions Votes % of Votes % of Total votes Total Votes
for votes Against votes cast votes with-held
cast cast cast as (2)
for against % of ISC
(1)
1. To adopt the
2020 Annual Report
and Accounts 126,557,317 99.87% 168,193 0.13% 126,725,510 12.93% 289,150
------------ ------- ---------- --------- ------------ ---------- -----------
2. To approve
the Directors'
Remuneration Policy 125,619,330 99.07% 1,177,033 0.93% 126,796,363 12.94% 218,297
------------ ------- ---------- --------- ------------ ---------- -----------
3. To approve
the Directors'
Remuneration Report 125,638,477 99.07% 1,177,033 0.93% 126,815,510 12.94% 199,150
------------ ------- ---------- --------- ------------ ---------- -----------
4. To reappoint
the Company's
auditor 126,528,170 99.87% 168,193 0.13% 126,696,363 12.93% 318,297
------------ ------- ---------- --------- ------------ ---------- -----------
5. To authorise
the Audit Committee
to determine the
auditor's remuneration 126,356,107 99.72% 350,256 0.28% 126,706,363 12.93% 308,297
------------ ------- ---------- --------- ------------ ---------- -----------
6. To re-elect
Sir Marc Feldmann
as a director
of the Company 125,895,121 99.28% 911,242 0.72% 126,806,363 12.94% 208,297
------------ ------- ---------- --------- ------------ ---------- -----------
7. To authorise
the Directors
to allot equity
securities 125,663,209 99.11% 1,133,154 0.89% 126,796,363 12.94% 218,297
------------ ------- ---------- --------- ------------ ---------- -----------
Special Resolutions Votes % of Votes % of Total votes Total Votes
for votes against votes cast votes with-held
cast cast cast as (2)
for against % of ISC
(1)
------------ ------- ---------- --------- ------------ ---------- -----------
8. To disapply
pre-emption provisions 123,047,368 97.04% 3,748,995 2.96% 126,796,363 12.94% 218,297
------------ ------- ---------- --------- ------------ ---------- -----------
9. To adopt new
Articles of Association 125,663,209 99.27% 923,154 0.73% 126,586,363 12.92% 428,297
------------ ------- ---------- --------- ------------ ---------- -----------
10. To adopt new
Articles of Association 126,014,268 99.36% 811,242 0.64% 126,825,510 12.94% 189,150
------------ ------- ---------- --------- ------------ ---------- -----------
(1) The Company's issued share capital ("ISC") on 23 June 2021,
being the date on which members had to be entered in the register
of members of the Company in order to be entitled to attend and
vote at the meeting, was 979,749,321 ordinary shares.
(2) A 'vote withheld' in respect of any resolution is not a vote
in law and is not counted in the calculation of the proportion of
the votes for and against it.
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive
Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director peter.redmond@hemogenyx.com
Tel: +44 (0)20 3470
SP Angel Corporate Finance LLP 0470
Matthew Johnson, Vadim Alexandre,
Adam Cowl
Tel: +44 (0)20 7469
Peterhouse Capital Limited 0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGDKPBNQBKDDAB
(END) Dow Jones Newswires
June 25, 2021 10:32 ET (14:32 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024
